Management of Hemolytic Uremic Syndrome in Pediatric Patients
Pediatric HUS must be treated as a medical emergency requiring immediate multidisciplinary team involvement, with complement inhibitor therapy (eculizumab or ravulizumab) initiated urgently for atypical HUS while providing intensive supportive care including renal replacement therapy when indicated. 1
Immediate Recognition and Classification
The first critical step is rapid etiological differentiation, as management differs substantially between subtypes:
- Atypical HUS (aHUS): Complement-mediated, requires specific complement blockade therapy
- STEC-HUS: Shiga toxin-producing E. coli, managed supportively
- Secondary HUS: Associated with systemic lupus erythematosus, infections, or other triggers
Key diagnostic pitfall: In pediatric patients, all three classic signs (hemolytic anemia, thrombocytopenia, renal involvement) may not be clearly present at onset in up to 50% of cases 1. In newborns and infants, aHUS can present without thrombocytopenia, anemia, or elevated creatinine 1. Always assess creatinine relative to age-specific norms 1.
Critical distinguishing feature for pediatrics: If diarrhea appears simultaneously with HUS symptoms or is very brief, suspect aHUS rather than STEC-HUS, which typically manifests 4-5 days after diarrhea onset 1.
Essential First-Line Investigations
Obtain immediately:
- Complete blood count with peripheral smear for schistocytes
- Direct and indirect Coombs test (must be negative for HUS diagnosis)
- LDH, haptoglobin (elevated LDH, reduced haptoglobin in 89.3% of cases) 2
- Renal function (creatinine, BUN - interpret age-appropriately)
- ADAMTS13 activity (urgent, to exclude TTP)
- Complement levels (C3, C4, CH50, AP50) - C3 low in 90% of cases 2
- Stool culture for STEC and Shiga toxin testing
- Urinalysis for proteinuria and hematuria
Immediate Management Algorithm
1. Supportive Care (All HUS Types)
- Admit to intensive care unit with pediatric nephrology consultation 1
- Fluid and electrolyte management: Monitor closely for hypokalemia (significantly associated with hypertension) 3
- Blood pressure control: HTN occurs in 48-54% of pediatric HUS cases and associates with cardiac complications 3
- Renal replacement therapy: Initiate peritoneal dialysis or hemodialysis when indicated (56% of patients require this acutely) 4
- Transfusion support: For severe anemia or bleeding, but avoid platelet transfusions unless life-threatening hemorrhage
2. Specific Therapy for Atypical HUS
Complement inhibition is the definitive treatment for aHUS and must be started immediately upon diagnosis 1:
- Eculizumab or Ravulizumab (both have equivalent efficacy; ravulizumab offers longer duration and less frequent dosing) 1
- Do NOT delay treatment waiting for genetic confirmation - absence of identified mutations does not exclude aHUS (40-50% have no identifiable mutation) 1
Mandatory infection prophylaxis with complement blockade 1:
- Meningococcal vaccination: Quadrivalent A, C, W, Y conjugate vaccine AND serogroup B vaccine (administer before treatment if possible, but do not delay therapy)
- Antibiotic prophylaxis: Penicillin for duration of complement inhibitor therapy (macrolides if penicillin-allergic)
3. Alternative/Adjunctive Therapy When Complement Inhibitors Unavailable
In resource-limited settings where eculizumab/ravulizumab are inaccessible 5, 6:
- Plasma exchange (plasmapheresis): Daily exchanges with fresh frozen plasma for first month
- Plasma infusion: If plasma exchange not feasible
- For anti-Factor H antibody-associated aHUS: Combine plasma exchange with immunosuppression (this subtype shows high prevalence in some populations) 5
Important caveat: Plasma therapy is empirical and based on limited evidence, but represents the only option when complement inhibitors are unavailable 6. This should only be undertaken in specialized pediatric nephrology centers 6.
4. STEC-HUS Management
- Supportive care only - no specific therapy proven effective 4, 5
- Avoid antibiotics (may worsen toxin release)
- Monitor for complications: Neurological involvement, severe hypertension
Multidisciplinary Team Composition
Essential team members 1:
- Pediatric nephrologist (lead)
- Pediatric intensivist
- Hematologist
- Emergency physician
- Neurologist (for neurological complications)
- Psychologist
- Family pediatrician for continuity
Genetic Testing and Counseling
- Perform next-generation sequencing of complement genes (CFH, CFHR1-5, C3, CD46, CFI, THBD, DGKE, CFB) 1
- Provide genetic counseling once diagnosis confirmed, as condition may have hereditary transmission 1
- Do not wait for results to initiate treatment - genetic testing guides long-term management and family planning, not acute therapy
Long-Term Follow-Up Strategy
Lifelong monitoring is mandatory 4, 3:
- Renal function surveillance: Creatinine, proteinuria, hematuria
- Blood pressure monitoring: Essential given 48% prevalence of hypertension and cardiac complications 3
- Cardiovascular assessment: Echocardiography for cardiac involvement
- Relapse monitoring: Clinical presentation + hemolysis markers + proteinuria + microhematuria 1
Prognosis reality: Despite optimal care, 23-25% develop chronic kidney disease, with some progressing to end-stage renal disease requiring transplantation 4, 2. One study showed 60% complete remission, but 10% developed CKD Stage 5 2.
Treatment Discontinuation Considerations
Stopping complement inhibitors carries significant risk of aHUS recurrence and renal failure 1. Thorough risk factor assessment is essential before any discontinuation decision. Patients with genetic mutations in complement regulatory proteins generally require indefinite therapy.
Key Pitfalls to Avoid
- Delaying treatment while awaiting genetic results or complete diagnostic workup
- Assuming normal creatinine excludes renal involvement in young children (use age-appropriate reference ranges)
- Diagnosing STEC-HUS based solely on diarrhea presence (timing and pattern matter)
- Starting complement inhibitors without meningococcal prophylaxis
- Discontinuing follow-up after acute recovery (late sequelae are common)